Study seeks data on Betadine irrigation for epidemic keratoconjunctivitis

A Web-based open-label trial is announcing a call for data on the use of 5% Betadine irrigation for adenovirus epidemic keratoconjunctivitis.

The full protocol calls for use of an in-office assay to confirm the diagnosis of adenovirus involvement. However, because some physicians may not have access to the test, the trial will also accept data for cases in which Betadine (5% povidone-iodine ophthalmic solution, Alcon) was used on clinically diagnosed keratoconjunctivitis, according to lead investigator Daniel B. Goldberg, MD.

The use of Betadine irrigation for keratoconjunctivitis has been suggested in the literature as far back as 30 years ago, Dr. Goldberg said in an interview with Ocular Surgery News, but "none of those studies would get to the level of any kind of scientific validation of the efficacy."

"What we want to do is simply establish efficacy for what is a low-cost therapy for a very common, worldwide, highly contagious and sometimes very severe conjunctivitis with the potential for long-term corneal complications," he said.

In an attempt to simplify the process and invite greater participation, all information on the study, including consent and examination forms, is available at www.betadineforekc.com. Initial data collection will end Oct. 1, Dr. Goldberg said.

The trial will require "several hundred cases at a minimum" to establish the efficacy of Betadine irrigation for keratoconjunctivitis, Dr. Goldberg said. The current study could spur future research on number of treatments required, the specific dose required and whether Betadine lowers the risk for secondary corneal infiltrates.

"The only way we can get enough cases is to collaborate," Dr. Goldberg said.

Dr. Goldberg said he has no financial interest in the study, nor do any of the other members of the coordinating committee, which includes Michael Su, MD, and Lisa Ortenzio, OD.